Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-192.87%
operating margin TTM
-156.69%
revenue TTM
9.60 Million
revenue per share TTM
0.47$
valuation ratios | |
|---|---|
| pe ratio | -4.63 |
| peg ratio | -0.51 |
| price to book ratio | 6.57 |
| price to sales ratio | 12.90 |
| enterprise value multiple | -8.74 |
| price fair value | 6.57 |
profitability ratios | |
|---|---|
| gross profit margin | 87.26% |
| operating profit margin | -156.69% |
| pretax profit margin | -193.55% |
| net profit margin | -192.87% |
| return on assets | -40.07% |
| return on equity | -356.81% |
| return on capital employed | -41.74% |
liquidity ratios | |
|---|---|
| current ratio | 4.24 |
| quick ratio | 4.24 |
| cash ratio | 0.62 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 7.52 |
| days of payables outstanding | 712.11 |
| cash conversion cycle | -704.59 |
| receivables turnover | 48.56 |
| payables turnover | 0.51 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.31 |
| debt equity ratio | 1.08 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.52 |
| interest coverage | -3.69 |
| cash flow to debt ratio | -2.06 |
cash flow ratios | |
|---|---|
| free cash flow per share | -13.51 |
| cash per share | 19.18 |
| operating cash flow per share | -13.47 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -2.06 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -310.03 |
Frequently Asked Questions
When was the last time Nektar Therapeutics (NASDAQ:NKTR) reported earnings?
Nektar Therapeutics (NKTR) published its most recent earnings results on 07-11-2025.
What is Nektar Therapeutics's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Nektar Therapeutics (NASDAQ:NKTR)'s trailing twelve months ROE is -356.81%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Nektar Therapeutics (NKTR) currently has a ROA of -40.07%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NKTR's net profit margin stand at?
NKTR reported a profit margin of -192.87% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NKTR's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.24 in the most recent quarter. The quick ratio stood at 4.24, with a Debt/Eq ratio of 1.08.